Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | Q04609 | - |
- |
Posttranslational Modification | Comment | Organism |
---|---|---|
acetylation | treatment with valproic acid increases the acetylation of glutamate carboxypeptidase II protein at the lysine residues and facilitates a decrease of the poly-ubiquitinated glutamate carboxypeptidase II level. Similarly, M344, a specific histone deacetylase 1/6 inhibitor, also increases the glutamate carboxypeptidase II protein level | Homo sapiens |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
astrocyte | - |
Homo sapiens | - |
U-87MG cell | - |
Homo sapiens | - |
Synonyms | Comment | Organism |
---|---|---|
GCPII | - |
Homo sapiens |
General Information | Comment | Organism |
---|---|---|
metabolism | acute exposure to valproic acid, a drug used for bipolar disorder and epilepsy and a known histone deacetylase inhibitor, for 4-6 h increases the glutamate carboxypeptidase II protein level in human astrocyte U-87MG cells but does not have a similar effect after 12-24 h exposure. Valproic acid does not affect the glutamate carboxypeptidase II mRNA expression, but decrease in glutamate carboxypeptidase II protein level by cycloheximide treatment is blocked by valproic acid. The valproic acid-induced increase of glutamate carboxypeptidase II protein level may be dependent on the ubiquitin/proteasome pathway. Valproic acid increases the acetylation of glutamate carboxypeptidase II protein at the lysine residues and facilitates a decrease of the poly-ubiquitinated glutamate carboxypeptidase II level. Similarly, M344, a specific histone deacetylase 1/6 inhibitor, also increases the glutamate carboxypeptidase II protein level | Homo sapiens |